276 related articles for article (PubMed ID: 31598934)
21. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
22. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
[TBL] [Abstract][Full Text] [Related]
23. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
24. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL
J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879
[TBL] [Abstract][Full Text] [Related]
25. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
26. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
27. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].
Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Tong HY; Hu C; Yu MX; Ma QL; Chen FF; Ye L; Wei JY; Xu GX; Mao LP; Li Y; Jin J
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3180-4. PubMed ID: 24405536
[TBL] [Abstract][Full Text] [Related]
31. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
32. [Molecular international prognostic scoring system for myelodysplastic syndromes].
Nagata Y
Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
[TBL] [Abstract][Full Text] [Related]
33. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.
Gangat N; Mudireddy M; Lasho TL; Finke CM; Nicolosi M; Szuber N; Patnaik MM; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2018 May; 93(5):691-697. PubMed ID: 29417633
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F; Robledo C; Izquierdo-García FM; Suárez-Vilela D; Benito R; Fuertes M; Insunza A; Barragán E; Del Rey M; García-Ruiz de Morales JM; Tormo M; Salido E; Zamora L; Pedro C; Sánchez-Del-Real J; Díez-Campelo M; Del Cañizo C; Sanz GF; Hernández-Rivas JM;
Oncotarget; 2016 May; 7(21):30492-503. PubMed ID: 27127180
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of different scoring systems and gene mutations for the prognosis of myelodysplastic syndrome (MDS) in Chinese population.
Du MY; Xu M; Deng J; Liu L; Guo T; Xia LH; Hu Y; Mei H
J Cancer; 2020; 11(2):508-519. PubMed ID: 31897246
[TBL] [Abstract][Full Text] [Related]
36. Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.
Horiike S; Kita-Sasai Y; Nakao M; Taniwaki M
Leuk Lymphoma; 2003 Jun; 44(6):915-22. PubMed ID: 12854888
[TBL] [Abstract][Full Text] [Related]
37. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Nat Med; 2020 Oct; 26(10):1549-1556. PubMed ID: 32747829
[TBL] [Abstract][Full Text] [Related]
38. A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With
Ma L; Liang B; Hu H; Yang W; Lin S; Cao L; Li K; Kuang Y; Shou L; Jin W; Lan J; Ye X; Le J; Lei H; Fu J; Lin Y; Jiang W; Zheng Z; Jiang S; Fu L; Su C; Yin X; Liu L; Qin J; Jin J; Qian S; Ouyang G; Tong H
Front Oncol; 2022; 12():905490. PubMed ID: 35832562
[TBL] [Abstract][Full Text] [Related]
39. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
40. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.
Haider M; Duncavage EJ; Afaneh KF; Bejar R; List AF
Am Soc Clin Oncol Educ Book; 2017; 37():480-494. PubMed ID: 28561687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
